Phase I study assessing the safety and pharmacokinetic profile of BV100 in healthy volunteers
Latest Information Update: 18 Oct 2024
Price :
$35 *
At a glance
- Drugs Rifabutin (Primary)
- Indications Bacterial infections; Ventilator associated pneumonia
- Focus Adverse reactions; Pharmacokinetics
- 16 Oct 2024 According to BioVersys media release, this trial is expected to start in 1H 2025 as part of our preparation for a global Phase 3 registration study.
- 17 Sep 2024 New trial record
- 11 Sep 2024 According to BioVersys media release, this Phase 1 is on track to be initiated by early 2025 and will be followed by the onboarding of Chinese patients into the planned global Phase 3 registrational study.